ArticleScientific reports2017
The prognostic significance of Cdc6 and Cdt1 in breast cancer.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 113 citations in OpenAlex.
- Overexpression of CDT1 inhibits cell cycle progression at S phase by interacting with the mini-chromosome maintenance complex and causes DNA damage.FEBS open bio · 2026Article
- Therapeutic efficacy monitoring in canine lymphoma patients via quantifying CDC6 plasma levels.BMC veterinary research · 2026Article
- BHLHE22, targeted by deubiquitinating enzyme OTUD3, exerts an antitumor role in triple-negative breast cancer progression via transcriptionally inhibiting CDT1.Breast cancer research : BCR · 2026Article
- Elevated expression of ANAPC1 in lung squamous cell carcinoma: clinical implications and mechanisms.Future science OA · 2025Article
- Royal Jelly Enhances the Sensitivity of Oral Squamous Cancer Cells to Paclitaxel, Suppressing Proliferation, Migration, and Glycolysis.Cell biochemistry and biophysics · 2025Article
- CDC6 promotes the development and progression of clear cell renal cell carcinoma via upregulating RRM2.Human cell · 2025Article
- Integrated machine learning and single-cell analysis identify chromatin-remodeling gene signature for diagnosis and prognosis in nasopharyngeal carcinoma.Clinical and experimental medicine · 2025Article
- A Distinguished Roadmap of Fibroblast Senescence in Predicting Immunotherapy Response and Prognosis Across Human Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Chromatin licensing and DNA replication factor 1 as a potential prognostic and diagnostic biomarker for gastric cancer.Scientific reports · 2024Article
- Exploring Bioinformatics Tools to Analyze the Role of CDC6 in the Progression of Polycystic Ovary Syndrome to Endometrial Cancer by Promoting Immune Infiltration.International journal of molecular sciences · 2024Article
- Comprehensive pan-cancer analysis reveals CDC6 as a potential immunomodulatory agent and promising therapeutic target in pancreatic cancer.Translational cancer research · 2024Article
- Article
- Deubiquitination of CDC6 by OTUD6A promotes tumour progression and chemoresistance.Molecular cancer · 2024Article
- CDC45 promotes the stemness and metastasis in lung adenocarcinoma by affecting the cell cycle.Journal of translational medicine · 2024Article
- Screening and verification of hub genes in esophageal squamous cell carcinoma by integrated analysis.Scientific reports · 2024Article
- Clinical significance ofJournal of clinical biochemistry and nutrition · 2024Article
- CDC6 overexpression contributes to the malignant phenotype of glioma via IL6/JAK2/STAT3 signaling.American journal of cancer research · 2024Article
- Non-canonical function of histone methyltransferase G9a in the translational regulation of chronic inflammation.Cell chemical biology · 2023Article
- The significance of CDT1 expression in non-cancerous and cancerous liver in cases with hepatocellular carcinoma.Journal of clinical biochemistry and nutrition · 2023Article
- CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma.BMC cancer · 2023Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DNA replication is a critical step in cell proliferation. Overexpression of MCM2-7 genes correlated with poor prognosis in breast cancer patients. However, the roles of Cdc6 and Cdt1, which work with MCMs to regulate DNA replication, in breast cancers are largely unknown. In the present study, we have shown that the expression levels of Cdc6 and Cdt1 were both significantly correlated with an increasing number of MCM2-7 genes overexpression. Both Cdc6 and Cdt1, when expressed in a high level, alone or in combination, were significantly associated with poorer survival in the breast cancer patient cohort (n = 1441). In line with this finding, the expression of Cdc6 and Cdt1 was upregulated in breast cancer cells compared to normal breast epithelial cells. Expression of Cdc6 and Cdt1 was significantly higher in ER negative breast cancer, and was suppressed when ER signalling was inhibited either by tamoxifen in vitro or letrozole in human subjects. Importantly, breast cancer patients who responded to letrozole expressed significantly lower Cdc6 than those patients who did not respond. Our results suggest that Cdc6 is a potential prognostic marker and therapeutic target in breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.